Business Description
Immunocore Holdings PLC
NAICS : 541714
SIC : 2834
ISIN : US45258D1054
Share Class Description:
FRA:6YG: ADRTotal Employee Number:
524Description
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.94 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 1.11 | |||||
Debt-to-EBITDA | 105.01 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.68 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 27.7 | |||||
3-Year EBITDA Growth Rate | 52 | |||||
3-Year EPS without NRI Growth Rate | 18.4 | |||||
3-Year FCF Growth Rate | 35.7 | |||||
3-Year Book Growth Rate | 2.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.97 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.67 | |||||
9-Day RSI | 63.65 | |||||
14-Day RSI | 63.38 | |||||
3-1 Month Momentum % | -8.21 | |||||
6-1 Month Momentum % | -12.77 | |||||
12-1 Month Momentum % | -18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.18 | |||||
Quick Ratio | 4.15 | |||||
Cash Ratio | 3.52 | |||||
Days Inventory | 512.25 | |||||
Days Sales Outstanding | 64.33 | |||||
Days Payable | 2030.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 1.12 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 98.86 | |||||
Operating Margin % | -8.35 | |||||
Net Margin % | -6.68 | |||||
EBITDA Margin % | 1.01 | |||||
FCF Margin % | -7.35 | |||||
OCF Margin % | -5.94 | |||||
ROE % | -7.11 | |||||
ROA % | -2.58 | |||||
ROIC % | -39.62 | |||||
3-Year ROIIC % | 35.14 | |||||
ROC (Joel Greenblatt) % | 1.61 | |||||
ROCE % | 0.09 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 268.57 | |||||
PS Ratio | 4.14 | |||||
PB Ratio | 4.32 | |||||
Price-to-Tangible-Book | 4.32 | |||||
EV-to-EBIT | 1639.75 | |||||
EV-to-EBITDA | 311.83 | |||||
EV-to-Forward-EBITDA | -30.23 | |||||
EV-to-Revenue | 3.13 | |||||
EV-to-Forward-Revenue | 2.79 | |||||
EV-to-FCF | -42.08 | |||||
Price-to-GF-Value | 0.72 | |||||
| Price-to-Net-Current-Asset-Value | 5.23 | |||||
| Price-to-Net-Cash | 10.25 | |||||
Earnings Yield (Greenblatt) % | 0.06 | |||||
FCF Yield % | -1.81 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunocore Holdings PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 354.781 | ||
| EPS (TTM) (€) | -0.469 | ||
| Beta | 1.5893 | ||
| 3-Year Sharpe Ratio | -0.34 | ||
| 3-Year Sortino Ratio | -0.47 | ||
| Volatility % | 34.35 | ||
| 14-Day RSI | 63.38 | ||
| 14-Day ATR (€) | 0.926371 | ||
| 20-Day SMA (€) | 27 | ||
| 12-1 Month Momentum % | -18 | ||
| 52-Week Range (€) | 23.2 - 35.6 | ||
| Shares Outstanding (Mil) | 50.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunocore Holdings PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunocore Holdings PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 114 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 08:00 | In 24 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 23 days | ||
| General meeting for 2026 | 2026-05-27 13:00 | 24.80 (+0.81%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 24.20 (+0.83%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 15:00 | 26.40 (-1.49%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 15:40 | 28.40 (+4.41%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-25 08:00 | 28.40 (+2.16%) | ||
| Annual report for 2025 | 2026-02-25 | 28.40 (+2.16%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 28.40 (+2.16%) |
Show
Entries
Immunocore Holdings PLC Frequently Asked Questions
What is Immunocore Holdings PLC(FRA:6YG)'s stock price today?
The current price of FRA:6YG is €28.80. The 52 week high of FRA:6YG is €35.60 and 52 week low is €23.20.
When is next earnings date of Immunocore Holdings PLC(FRA:6YG)?
The next earnings date of Immunocore Holdings PLC(FRA:6YG) is 2026-08-07 Est..
Does Immunocore Holdings PLC(FRA:6YG) pay dividends? If so, how much?
Immunocore Holdings PLC(FRA:6YG) does not pay dividend.
Press Release
Articles on Immunocore Holdings PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers